Home / Companies / King Legacy, a wholly owned subsidiary of Pfizer

King Legacy, a wholly owned subsidiary of Pfizer

FDA Regulatory Profile

Summary

Total Recalls
11
510(k) Clearances
0
Inspections
0
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-427-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-count bottles (NDC 60793-85April 30, 2013
D-426-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-count bottles (NDC 60793-85April 30, 2013
D-428-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-count bottles (NDC 60793-85April 30, 2013
D-421-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count bottles (NDC 60793-850April 30, 2013
D-431-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-86April 30, 2013
D-424-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count bottles (NDC 60793-853April 30, 2013
D-425-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-count bottles (NDC 60793-85April 30, 2013
D-422-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count bottles (NDC 60793-851April 30, 2013
D-430-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-count bottles (NDC 60793-85April 30, 2013
D-423-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count bottles (NDC 60793-852April 30, 2013
D-429-2013Class IILevoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-85April 30, 2013